abrdn plc Grows Holdings in Hologic, Inc. (NASDAQ:HOLX)

abrdn plc increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 23.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 358,271 shares of the medical equipment provider’s stock after buying an additional 68,920 shares during the period. abrdn plc owned about 0.15% of Hologic worth $25,598,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nordea Investment Management AB increased its stake in Hologic by 4.5% during the 3rd quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock worth $113,077,000 after buying an additional 69,494 shares during the period. Pathstone Family Office LLC increased its position in shares of Hologic by 96.0% in the 3rd quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock worth $643,000 after purchasing an additional 4,542 shares during the last quarter. Ontario Teachers Pension Plan Board increased its position in shares of Hologic by 186.7% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock worth $2,665,000 after purchasing an additional 25,010 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt increased its position in shares of Hologic by 145.3% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 468 shares during the last quarter. Finally, HB Wealth Management LLC increased its position in shares of Hologic by 18.1% in the 3rd quarter. HB Wealth Management LLC now owns 5,774 shares of the medical equipment provider’s stock worth $401,000 after purchasing an additional 884 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 1.3 %

Hologic stock opened at $77.19 on Wednesday. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average price of $75.87 and a two-hundred day moving average price of $72.69. The firm has a market capitalization of $18.12 billion, a price-to-earnings ratio of 36.58, a PEG ratio of 2.58 and a beta of 1.00. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $87.88.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. Hologic’s revenue was down 5.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.07 EPS. Sell-side analysts expect that Hologic, Inc. will post 4.01 earnings per share for the current year.

Insider Buying and Selling at Hologic

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now owns 48,611 shares in the company, valued at $3,670,130.50. The disclosure for this sale can be found here. Insiders sold 32,846 shares of company stock valued at $2,473,443 in the last ninety days. Company insiders own 1.75% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on HOLX shares. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. UBS Group boosted their target price on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Evercore ISI boosted their target price on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a research report on Wednesday, April 10th. Finally, Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $87.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.